AIGen Therapeutics

AIGen Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule drugs through its proprietary artificial intelligence platform. Founded in 2021 and headquartered in Suzhou, China, the company focuses on high-value targets in oncology and immunology, with a particular emphasis on DNA damage repair pathways. Their lead program, AIG-101, is a selective USP1 inhibitor that has received FDA IND clearance for the treatment of solid tumors with homologous recombination deficiencies. AIGen leverages its AI capabilities to significantly shorten the drug discovery cycle and improve the success rate of lead optimization. The company's leadership team includes industry veterans with extensive experience in global pharmaceutical R&D, including former executives from Johnson & Johnson. AIGen is supported by a strong syndicate of investors, including Qiming Venture Partners and Eight Roads.